Pharmacy benefit managers (PBMs) significantly impact GTN revenue through rebates, but patient access issues persist due to ...

At ASN Kidney Week 2025, Glucagon-like peptide-1 (GLP-1) receptor agonists moved firmly into the nephrology spotlight, with ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Zenas's strong balance sheet, with $301.6M in cash and runway into late 2026, supports aggressive late-stage pipeline ...

Eli Lilly's new obesity drug shows promising results in weight loss, surpassing its existing drug Zepbound, as competition in ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Important state and national stories, market and business news, sports and entertainment, delivered in quick-hit fashion ...

Lilly is investigating the triple G agonist retatrutide in seven other Phase III trials, which are due to read out in 2026.

The company also said earlier this week it will drop $6 billion on a new manufacturing facility in Huntsville, Alabama.

In a significant move to address supply constraints, Eli Lilly announced a $6 billion investment to construct a new manufacturing facility in Huntsville, Alabama. This site is slated to produce both ...

Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of ...

The coming year, 2026, is shaping up as a critical operational and financial test. A head-to-head comparative study between Novo Nordisk's CagriSema and Eli Lilly's Zepbound, scheduled for 2026, will ...